BioWorld Science

Aug. 8, 2016

View Archived Issues

Vyriad enters global license agreement with Stinginn

Read More

Eisai reviews accomplishments of first quarter of fiscal 2016

Read More

Merck & Co. patents BACE1 and -2 inhibitors

Read More

Sumitomo Dainippon Pharma discloses Nav1.7 channel blockers

Read More

Millennium Pharmaceuticals describes Nampt inhibitors

Read More

Scripps Research Institute develops MCT1 and/or MCT4 inhibitors

Read More

MyoKardia presents cardiac myosin activators

Read More

MMRF and University of Michigan collaborate on a new molecular profiling initiative

Read More

Autologous BMC is safe and effective in treating patients with atrophic non-unions

Read More

FDA accepts Merck & Co.'s MK-1293 NDA for review

Read More

Mylan completes public offer settlement with Meda

Read More

CheckMate 026 phase III study of Opdivo does not meet primary endpoint

Read More

ZSYM73 affibody in a mouse model of AD

Read More

Shire reports recent developments of second quarter 2016

Read More

UT Southwestern receives funding from NCI to target rising rates of kidney cancer

Read More

Hematogenix announces launch of Ventana PD-L1 (SP142) and (SP263) assays

Read More

FDA approves Merck & Co.'s Keytruda for patients with recurrent or metastatic HNSCC

Read More

Lantern Pharma to evaluate BioNumerik's Tavocept

Read More

FDA grants orphan drug designation to vedolizumab

Read More

Boehringer Ingelheim begins phase II trial of BI-425809 in patients with schizophrenia

Read More

Phase II trial of volixibat in patients with NASH recruiting patients

Read More

Tolerogenic nanoparticles improve biologic drug efficacy

Read More